Here is why TherapeuticsMD jumped 300%

0

Here is why TherapeuticsMD jumped 300% | Invezz

Ad disclosure

Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >

By:

Ruchi Gupta

on
May 31, 2022

TherapeuticsMD enters definitive agreement to merge with EW Healthcare Partners

Transaction to cost around $177 million

TherapeuticsMD is an opportunity for Majorelle to expand to the US

TherapeuticsMD Inc. (NASDAQ: TXMD) surged 300% after the women’s healthcare firm announced the signing of a definitive agreement to be purchased by an EW Healthcare Partners affiliate. EW Healthcare Partners is a private equity company committed to investing in fast-growing healthcare firms.

EW Healthcare Partners to acquire TherapeuticsMD for $177 million

According to the terms of the agreement, which has received 100% support from TXMD’s board, EW Healthcare Partners shall initiate a tender offer to purchase all outstanding TXMD shares in a cash consideration at $10 per share to complete a merger. The total value of the transaction is estimated to be around $177 million. The acquisition price is 367.3% higher than TXMD’s closing price on May 27, 2022.


Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

CEO TherapeuticsMD Hugh O’Dowd said:

We are very pleased to enter into this agreement with EW Healthcare Partners. Together, we will continue empowering women of all ages through a therapeutic focus in family planning, reproductive health, and menopause management. We have a deep appreciation for EW Healthcare Partner’s depth of expertise and track record and know they will bring an incredible value of knowledge and strategic guidance.

With over $4 billion in money raised since its establishment, EW Healthcare Partners is among the oldest and largest private healthcare venture organizations. EW Healthcare Partners has invested in over 150 fast-growing healthcare companies in  Europe and the US in medical devices, pharmaceuticals, technology-enabled services, and diagnostics.

EW Healthcare Partners Evis Hursever commented:

We are pleased to welcome TherapeuticsMD to the EW Healthcare Partners portfolio and are deeply committed to the Company’s mission of advancing women’s health. EW Healthcare Partners has already made a significant investment in women’s health through its acquisition of Majorelle.

TherapeuticsMD is an opportunity for Majorelle to expand to the US

TherapeuticsMD is a once-in-a-lifetime chance for Majorelle to break into the US arena, and it fits perfectly with EW Healthcare’s ambitious goals to build a leading trans-Atlantic women’s health platform.

Majorelle chairman and senior advisor of EW Healthcare Partners Oliver Bohuon said:

We look forward to working together with the company’s management team to enhance the patient experience, improve operational efficiency and create one of a very few trans-Atlantic specialty pharma companies dedicated to women’s health.

Invest in crypto, stocks, ETFs & more in minutes with our preferred broker,
Capital.com

9.3/10

75.26% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

Visit site

Health & pharmaceuticals


Stocks & Shares

Generated by Feedzy